| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 261 | Oligosaccharides and glycoproteins produced in milk of transgenic non-human mammals | US433271 | 1995-05-02 | US5891698A | 1999-04-06 | Pedro Antonio Prieto; David Fletcher Smith; Richard Dale Cummings; John Joseph Kopchick; Pradip Mukerji; Kelley Wilson Moremen; James Michael Pierce |
| The invention relates to humanized milk. The milk is produced by a non-human transgenic mammal wherein the genome of said transgenic non-human mammal contains at least one heterologous gene encoding for a human catalytic entity and wherein the catalytic entity produces oligosaccharides and glycoconjugates that are present in the milk of said transgenic non-human mammal. An especially useful catalytic entity is human glycosyltransferases which produce oligosaccharides and glyconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter. A method of obtaining humanized milk is disclosed. The method comprises the steps of (a) inserting into the genome of a non-human mammal a heterologous gene encoding the production of a human catalytic entity wherein said catalytic entity produces a secondary gene product in the milk of said non-human mammal; and (b) milking said non-human mammal. The humanized milk may be used in the preparation of an enteral nutritional product useful in the nutritive maintenance of an animal. | ||||||
| 262 | Transgenic non-human mammals that express human BSSL/CEL | US442806 | 1995-05-17 | US5716817A | 1998-02-10 | Jan Birger Fredrik Tornell |
| The present invention relates to a DNA molecule containing intron sequences and encoding a human protein which is, depending on the site of action, called Bile Salt-Stimulated Lipase (BSSL) or Carboxyl Ester Lipase (CEL). The DNA molecule is advantageously used in the production of recombinant human BSSL/CEL, preferably by means of production in transgenic non-human mammals. The recombinant human BSSL/CEL can be used as a constituent of infant formulas used for feeding infants as a substitute for human milk, or in the manufacture of medicaments against e.g. fat malabsorption, cystic fibrosis and chronic pancreatitis. | ||||||
| 263 | Human recombinant collagen in the milk of transgenic animals | US183648 | 1994-01-18 | US5667839A | 1997-09-16 | Richard A. Berg |
| Production of human procollagen or collagen in cells which ordinarily do not produce these molecules is effected by constructing expression systems compatible with mammary glands of non-human mammals. For example, expression systems can be microinjected into fertilized oocytes and reimplanted in foster mothers and carried to term in order to obtain transgenic non-human mammals capable of producing milk containing recombinant human procollagen or collagen. Human procollagen or collagen produced in this manner can be made of a single collagen type uncontaminated by other human or non-human collagens. | ||||||
| 264 | Genomic DNA sequences encoding human BSSL/CEL | US68945 | 1993-05-27 | US5616483A | 1997-04-01 | Karl G. Bjursell; Peter N. I. Carlsson; Curt S. M. Enerback; Stig L. Hansson; Ulf F. P. Lidberg; Jeanette A. Nilsson; Jan B. F. Tornell |
| The present invention relates to a DNA molecule containing intron sequences and encoding a human protein which is, depending on the site of action, called Bile Salt-Stimulated Lipase (BSSL) or Carboxyl Ester Lipase (CEL). The DNA molecule is advantageously used in the production of recombinant human BSSL/CEL, preferably by means of production in transgenic non-human mammals. The recombinant human BSSL/CEL can be used as a constituent of infant formulas used for feeding infants as a substitute for human milk, or in the manufacture of medicaments against e.g. fat malabsorption, cystic fibrosis and chronic pancreatitis. | ||||||
| 265 | DNA sequences to target proteins to the mammary gland for efficient secretion | US185574 | 1994-01-24 | US5565362A | 1996-10-15 | Jeffrey M. Rosen |
| Described is a method of targeting specific genes to the mammary gland which results in the efficient synthesis and secretion of biologically important molecules. Further, there is described as a composition of matter, a transgenic mammal having the ability to reproduce itself and being suitable for the secretion of biologically active agents into its milk. Additionally there is disclosed as a composition of matter, recombinant DNA gene complexes designed to integrate into a mammalian genome and to synthesize and secrete biological active agents into the milk. Furthermore methods of producing and using altered milk are disclosed. | ||||||
| 266 | Method for producing a formulated milk for infants analogous to human milk | US991397 | 1992-12-16 | US5436020A | 1995-07-25 | Tamotsu Kuwata; Tetsuo Kaneko; Tadashi Kojima; Toshitaka Kobayashi; Yoshiro Yamamoto |
| The present invention provides formulated milk compositions for infants analogous to human milk in which non-protein nitrogen components are abundant and the contents of .beta.-lactoglobulin and/or .alpha..sub.S casein are reduced. | ||||||
| 267 | DNA sequences to target proteins to the mammary gland for efficient secretion | US602066 | 1990-10-24 | US5304489A | 1994-04-19 | Jeffrey M. Rosen |
| Described is a method of targeting specific genes to the mammary gland which results in the efficient synthesis and secretion of biologically important molecules. Further, there is described as a composition of matter, a transgenic mammal having the ability to reproduce itself and being suitable for the secretion of biologically active agents into its milk. Additionally there is disclosed as a composition of matter, recombinant DNA gene complexes designed to integrate into a mammalian genome and to synthesize and secrete biological active agents into the milk. Furthermore methods of producing and using altered milk are disclosed. | ||||||
| 268 | Infant formula | US526096 | 1990-05-21 | US5013569A | 1991-05-07 | David Rubin |
| An infant food formulation substantially approximating human milk in fatty acid composition comprising a mixture of DHA and EPA in a ratio of approximately 3:2 by weight, immunoglobulins to mimic the immunoglobulin content of mother's milk, a source of protein, a source of carbohydrate, a source of ash, and sufficient water to provide an easily assimilable infant formula, the DHA, the EPA, and the immunoglobulins being encapsulated in capsules having a diameter of less than 350.mu.. | ||||||
| 269 | Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili | US933358 | 1986-11-19 | US4971794A | 1990-11-20 | Margaret A. Linggood; Philip Porter; Jonathan R. Powell |
| Antibodies are produced by hyperimmunizing a mammal, such as cow, with a vaccine derived from E. coli bacteria. The bacterial strains in the vaccine are selected on the basis of their virulence characteristics, especially adhesion factors (pili), associated with gastroenteric disease in humans. The antibodies can be recovered from the mammal's milk or serum, and used in human foods. | ||||||
| 270 | Process for producing bifidogenic infant and dietetic foods reduced in antigenicity | US243804 | 1988-09-13 | US4963384A | 1990-10-16 | Willi Heine; Klaus-Dieter Wutzke |
| The present invention relates a process for the production of liquid and powdered bifidogenic infant and dietetic foods that are reduced in their antigenicity. The process, according to the invention, is characterized by the cleavage, but not removal, of sialic acid from milk protein and/or milk protein degradation products, via acid hydrolysis, in order to achieve a bifidogenic product. Thus, it is possible to produce bifidogenic infant foods, particularly suitable for infants, premature and undersized babies, and those parties who cannot tolerate usual milk products. In addition, the process can be used to produce dietetic food, particularly for persons suffering from intestinal allergies, other allergic diseases and failure of the liver and kidney. | ||||||
| 271 | Anti-inflammatory factor, method of isolation, and use | US177223 | 1988-04-04 | US4956349A | 1990-09-11 | Lee R. Beck |
| The invention relates to a substantially pure antiinflammatory factor isolated from milk collected from a milk producing animal, to the purification, identification, and characterization of said factor, and to a method for treating inflammation in an animal which comprises administering to the animal an anti-inflammatorally effective amount of the anti-inflammatory factor. In a preferred embodiment, the factor is isolated from milk is produced by a milk producing animal maintained in a hyperimmunized state. | ||||||
| 272 | Method for treating disorders of the vascular and pulmonary systems | US1848 | 1987-01-09 | US4897265A | 1990-01-30 | Ralph J. Stolle; Lee R. Beck |
| A method for treating vascular disorders or pulmonary disorders associated with smoking in an animal which comprises: administering to the animal milk collected from a bovid being maintained in a hyperimmune state, in an amount and for a time sufficient to produce anti arteriosclerotic or antiaging vascular effects or sparing effects on lung tissue. | ||||||
| 273 | Baby food preparation | US8149470 | 1970-10-16 | US3803311A | 1974-04-09 | HO B |
| A BABY FOOD IS PREPARED THAT IS PARTICULARLY SUITABLE FOR INFANTS IN REDUCING DIGESTION PROBLEMS WHILE SIMULTANEOUSLY MEETING MAJOR NUTRITIONAL REQUIREMENTS. THE FOOD CONTAINS ABOUT 2 TABLESPOONS OF CORNSTARCH PER QUART OF WATER, ABOUT 4 OZ. OF MILK PER 4 OZ. OF A HOMOGENEOUS COLLOIDAL SUSPENSION OF CORNSTARCH AND ABOUT 4 TABLESPOONS OF SUGAR PER QUART OF THE WATER. THE METHOD FOR MAKING THE FOOD INVOLVES PREPARING THE CORNSTARCH INTO A HOMOGENEOUS COLLOIDAL SUSPENSION AND THEREAFTER ADMIXING THE MOLK.
|
||||||
| 274 | Infant's formula made with electrodialyzed milk | US33023163 | 1963-12-13 | US3320072A | 1967-05-16 | CLARK ROBERT E; SPENCE ELBERT R; STRIBLEY REXFORD C |
| 275 | Milk treatment process | US21384451 | 1951-03-05 | US2710808A | 1955-06-14 | PCEBLES DAVID D; CLARY JR PAUL D |
| 276 | Process for preparing condensed low lactose skim milk for storage and recovery of lactose therefrom | US36650240 | 1940-11-20 | US2349227A | 1944-05-16 | THORNELOE AVA S |
| 277 | Method for reducing the viscosity of a colloidal suspension of proteins | US58458232 | 1932-01-02 | US1952017A | 1934-03-20 | ALAN LEIGHTON; ABRAHAM LEVITON |
| 278 | Powdered acid milk and process of preparing same | US27014628 | 1928-04-14 | US1882638A | 1932-10-11 | JOHNSON LAMBERT D; TRUE NATHAN F |
| 279 | Process of preparing a food | US65983023 | 1923-08-28 | US1532005A | 1925-03-31 | HASELEN HERMANUS VAN |
| 280 | BLACK-EYED PEA PROTEIN ISOLATES, PRODUCTS, AND METHODS | US16268083 | 2019-02-05 | US20190239535A1 | 2019-08-08 | Keswara Rao Vadlamani |
| Embodiments herein include methods for producing black-eyed pea protein isolates and food and beverage products including the same. In an embodiment, a method can include tempering black-eyed pea seeds to 35-45% moisture content and holding 30-120 min, cracking the tempered seeds to loosen the hull and the meat, and separating these two fractions. The method can further include wet-grinding the meat fraction to a finer mash and lowering the pH of the black-eyed pea mash to about 1 to 3 in an aqueous solvent. The method can further include separating an acidic wet cake out from the acidic protein liquid fraction and raising the pH of the acidic wet cake to about 9 to 11 in an aqueous solvent. The method can further include separating alkaline wet cake out from the alkaline protein liquid fraction and combining the acid and alkali protein liquid fractions. Other embodiments are also included herein. | ||||||
QQ群二维码
意见反馈
意见反馈